Drug intelligence / Profile preview

NTZ-1010

Development stage: Preclinical
Lead developer: NTZ Lab
Modality: Small Molecules

Overview

NTZ-1010 is a selective monoamine oxidase B (MAO-B) inhibitor being developed by NTZ Lab as a small molecule therapeutic candidate for central nervous system (CNS) disorders. By targeting the MAO-B isoform, the compound aims to modulate CNS monoamine metabolism, which is relevant for the treatment of neurodegenerative and psychiatric conditions. It is currently in the preclinical stage of development for indications including Parkinson's disease, Alzheimer's disease, dementia, and depression.

Targets

MAOB (Monoamine oxidase B)

Beyond the preview

Go deeper on NTZ-1010.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NTZ-1010.

Explore the full profile